CE9A215 (inotodiol), a lanostane-type oxysterol, mitigates LPS-induced sepsis through multifaceted mechanisms

• Published in: European journal of pharmacology 2024-10, Vol.980, p.176836, Article 176836
• Main Authors: Nguyet Nguyen, Thi Minh, Park, Hyunah, Do, Thi Thuong, Kwak, Ji-Yun, Lee, Chang-kyu, Lee, Seung Hoon, Park, Jong-Il, Yoon, Sun-Young, Kim, Hyunjung, Park, Jihyun, Park, Jong-Tae
• Format: Article
• Language: English
• Subjects: Animals; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; ATP Binding Cassette Transporter 1 - metabolism; Cytokines - metabolism; Humans; Lanosterol - analogs & derivatives; Lanosterol - pharmacology; Lanosterol - therapeutic use; Lipopolysaccharides; Macrophage; Male; Mast cell; Mast Cells - drug effects; Mast Cells - immunology; Mast Cells - metabolism; Mice; Oxysterol; PLTP; RAW 264.7 Cells; Sepsis; Sepsis - chemically induced; Sepsis - drug therapy; Sepsis - metabolism
• ISSN: 0014-2999; 1879-0712; 1879-0712
• DOI: 10.1016/j.ejphar.2024.176836

Dysregulated host response against infection triggers sepsis that leads to multiple organ dysfunction due to uncontrolled inflammatory responses. Despite marked progress in understanding of sepsis, numerous clinical trials for treatment of sepsis have proven daunting and a new therapeutic approach is highly needed. CE9A215 (inotodiol), a fungal secondary metabolite, has been researched for its pharmacological activities and has shown potent anti-allergic effects. In this study, we evaluated the anti-inflammatory activities of CE9A215 upon lipopolysaccharide (LPS) stimulation in vivo and in vitro for the first time. CE9A215 decreased the production of interleukin (IL)-6, tumor necrosis factor alpha (TNF-α), and IL-1β in a concentration-dependent manner in LPS-stimulated RAW264.7 cells. Intriguingly, in human mast cell line LUVA, CE9A215 significantly lowered IL-4 and IL-10, and this effect could be beneficial for the clearance of bacterial infection. In addition, administration of CE9A215 improved the survival rate of LPS-stimulated mice and inhibited the pro-inflammatory cytokines, IL-6, TNF-α, and IL-1β in blood. Moreover, CE9A215 enhanced the expression levels of plasma phospholipid transfer protein (PLTP), apolipoprotein E (ApoE), and ATP-binding cassette transporter (ABCA1) in LPS-stimulated RAW246.7 cells. Liver PLTP level increased significantly in the CE9A215-administered group compared with the control group, which implies that CE9A215 promotes LPS clearance and neutralization by reverse transport of LPS by increasing the expressions of PLTP, ApoE, and ABCA1. Our results highlight CE9A215's potential as a novel therapeutic option for the treatment of sepsis.